Cancer nanomedicine: From targeted delivery to combination therapy

Trends in Molecular Medicine

Volumn 21, Issue 4, 2015, Pages 223-232

  Xu, Xiaoyang ^a,b,c   Ho, William ^a   Zhang, Xueqing ^a   Bertrand, Nicolas ^a,b   Farokhzad, Omid ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c NEW JERSEY INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Cancer; Combination therapy; Nanomedicine; Targeted delivery

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTARABINE PLUS DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; FLOXURIDINE; IRINOTECAN; LIPOSOME; NANOPARTICLE; NAVELBINE; OXALIPLATIN; PACLITAXEL; POLYLACTIC ACID; POLYMER; PROTEIN P53; SMALL INTERFERING RNA; TANESPIMYCIN; TRASTUZUMAB; ANTINEOPLASTIC AGENT; DELAYED RELEASE FORMULATION; DRUG CARRIER;

ACUTE GRANULOCYTIC LEUKEMIA; AMYLOIDOSIS; BLOOD VESSEL PERMEABILITY; CANCER THERAPY; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; HUMAN; MOLECULARLY TARGETED THERAPY; NANOMEDICINE; NON SMALL CELL LUNG CANCER; PARTICLE SIZE; REVIEW; SOLID TUMOR; TUMOR VASCULARIZATION; ANIMAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DISEASE MODEL; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PROCEDURES; RNA INTERFERENCE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; HUMANS; NANOMEDICINE; NANOPARTICLES; NEOPLASMS; RNA INTERFERENCE;

EID: 84925769724     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2015.01.001     Document Type: Review

References (79)

1. Sanna V., et al. Targeted therapy using nanotechnology: focus on cancer. Int. J. Nanomed. 2014, 9:467-483.
2. Farokhzad O.C., Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009, 3:16-20.
3. Chrastina A., et al. Overcoming in vivo barriers to targeted nanodelivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2011, 3:421-437.
4. Davis M.E., et al. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 2008, 7:771-782.
5. Zhang X.Q., et al. Interactions of nanomaterials and biological systems: implications to personalized nanomedicine. Adv. Drug Deliv. Rev. 2012, 64:1363-1384.
6. Chow E.K.H., Ho D. Cancer nanomedicine: from drug delivery to imaging. Sci. Transl. Med. 2013, 5:216rv4.
7. Whitehead K.A., et al. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 2009, 8:129-138.
8. Shi J., et al. Differentially charged hollow core/shell lipid-polymer-lipid hybrid nanoparticles for small interfering RNA delivery. Angew. Chem. Int. Ed. Engl. 2011, 50:7027-7031.
9. Reynolds A., et al. Induction of the interferon response by siRNA is cell type- and duplex length-dependent. RNA 2006, 12:988-993.
10. Kamaly N., et al. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem. Soc. Rev. 2012, 41:2971-3010.
11. Rao J.P., Geckeler K.E. Polymer nanoparticles: preparation techniques and size-control parameters. Prog. Polym. Sci. 2011, 36:887-913.
12. Capretto L., et al. Microfluidic and lab-on-a-chip preparation routes for organic nanoparticles and vesicular systems for nanomedicine applications. Adv. Drug Deliv. Rev. 2013, 65:1496-1532.
13. Whitesides G.M. The origins and the future of microfluidics. Nature 2006, 442:368-373.
14. Valencia P.M., et al. Microfluidic technologies for accelerating the clinical translation of nanoparticles. Nat. Nanotechnol. 2012, 7:623-629.
15. Lim J.M., et al. Ultra-high throughput synthesis of nanoparticles with homogeneous size distribution using a coaxial turbulent jet mixer. ACS Nano 2014, 8:6056-6065.
16. Valencia P.M., et al. Microfluidic platform for combinatorial synthesis and optimization of targeted nanoparticles for cancer therapy. ACS Nano 2013, 7:10671-10680.
17. Lim J.M., et al. Parallel microfluidic synthesis of size-tunable polymeric nanoparticles using 3D flow focusing towards in vivo study. Nanomedicine 2014, 10:401-409.
18. Windbergs M., et al. Biodegradable core-shell carriers for simultaneous encapsulation of synergistic actives. J. Am. Chem. Soc. 2013, 135:7933-7937.
19. Choi C-H., et al. One step formation of controllable complex emulsions: from functional particles to simultaneous encapsulation of hydrophilic and hydrophobic agents into desired position. Adv. Mater. 2013, 25:2535.
20. Harris J.M., Chess R.B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2003, 2:214-221.
21. Jokerst J.V., et al. Nanoparticle PEGylation for imaging and therapy. Nanomedicine 2011, 6:715-728.
22. Gref R., et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf. B. Biointerfaces 2000, 18:301-313.
23. Peracchia M.T., et al. Visualization of in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticles. Biomaterials 1999, 20:1269-1275.
24. Bazile D., et al. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J. Pharm. Sci. 1995, 84:493-498.
25. Peracchia M.T., et al. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J. Control. Release 1999, 60:121-128.
26. Radovic-Moreno A.F., et al. Surface charge-switching polymeric nanoparticles for bacterial cell wall-targeted delivery of antibiotics. ACS Nano 2012, 6:4279-4287.
27. Hatakeyama H., et al. A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. Adv. Drug Deliv. Rev. 2011, 63:152-160.
28. Yang W., et al. Poly(carboxybetaine) nanomaterials enable long circulation and prevent polymer-specific antibody production. Nano Today 2014, 9:10-16.
29. Keefe A.J., Jiang S. Poly(zwitterionic)protein conjugates offer increased stability without sacrificing binding affinity or bioactivity. Nat. Chem. 2012, 4:59-63.
30. Zhu Y., et al. A robust graft-to strategy to form multifunctional and stealth zwitterionic polymer-coated mesoporous silica nanoparticles. Biomacromolecules 2014, 15:1845-1851.
31. Yuan Y.Y., et al. Surface charge switchable nanoparticles based on zwitterionic polymer for enhanced drug delivery to tumor. Adv. Mater. 2012, 24:5476-5480.
32. Alexis F., et al. Nanoparticle technologies for cancer therapy. Handb. Exp. Pharmacol. 2010, 197:55-86.
33. Rodriguez P.L., et al. Minimal "self" peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 2013, 339:971-975.
34. Hu C.M., et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:10980-10985.
35. Weiss G.J., et al. First-in-human Phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Invest. New Drugs 2013, 31:986-1000.
36. Karve S., et al. Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:8230-8235.
37. Acharya S., Sahoo S.K. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv. Drug Deliv. Rev. 2011, 63:170-183.
38. Maeda H., et al. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur. J. Pharm. Biopharm. 2009, 71:409-419.
39. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev. 2011, 63:131-135.
40. Bertrand N., et al. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 2014, 66:2-25.
41. Fang J., et al. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 2011, 63:136-151.
42. Maeda H., et al. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug Deliv. Rev. 2013, 65:71-79.
43. Venditto V.J., Szoka F.C. Cancer nanomedicines: so many papers and so few drugs!. Adv. Drug Deliv. Rev. 2013, 65:80-88.
44. ® - the first FDA-approved nano-drug: lessons learned. J. Control. Release 2012, 160:117-134.
45. Matsumura Y.M. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 1986, 46:6387-6392.
46. Semple S.C., et al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 2010, 28:172-176.
47. Coelho T., et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 2013, 369:819-829.
48. Shi W., et al. Significance of Plk1 regulation by miR-100 in human nasopharyngeal cancer. Int. J. Cancer 2010, 126:2036-2048.
49. Wan C., et al. Lipid nanoparticle delivery systems for siRNA-based therapeutics. Drug Deliv. Transl. Res. 2013, 4:74-83.
50. Danquah M.K., et al. Extravasation of polymeric nanomedicines across tumor vasculature. Adv. Drug Deliv. Rev. 2011, 63:623-639.
51. Albanese A., et al. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu. Rev. Biomed. Eng. 2012, 14:1-16.
52. Peer D., et al. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2:751-760.
53. Ge Z., Liu S. Functional block copolymer assemblies responsive to tumor and intracellular microenvironments for site-specific drug delivery and enhanced imaging performance. Chem. Soc. Rev. 2013, 42:7289-7325.
54. Valencia P.M., et al. Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles. Biomaterials 2011, 32:6226-6233.
55. Davis M.E. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol. Pharm. 2009, 6:659-668.
56. Davis M.E., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
57. Zhang X.Q., et al. Multimodal nanodiamond drug delivery carriers for selective targeting, imaging, and enhanced chemotherapeutic efficacy. Adv. Mater. 2011, 23:4770-4775.
58. Leamon C.P., Low P.S. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:5572-5576.
59. Sega E.I., Low P.S. Tumor detection using folate receptor-targeted imaging agents. Cancer Metastasis Rev. 2008, 27:655-664.
60. Hrkach J., et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med. 2012, 4:128ra139.
61. Johnston A.P., et al. Targeting cancer cells: controlling the binding and internalization of antibody-functionalized capsules. ACS Nano 2012, 6:6667-6674.
62. Steichen S.D., et al. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur. J. Pharm. Sci. 2012, 48:416-427.
63. Mahon E., et al. Designing the nanoparticle-biomolecule interface for "targeting and therapeutic delivery". J. Control. Release 2012, 161:164-174.
64. Iyer A.K., et al. Role of integrated cancer nanomedicine in overcoming drug resistance. Adv. Drug Deliv. Rev. 2013, 65:1784-1802.
65. Douillard J-Y., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer [Adjuvant Navelbine International Trialist Association (ANITA)]: a randomised controlled trial. Lancet Oncol. 2006, 7:719-727.
66. Robert N., et al. Randomized Phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2006, 24:2786-2792.
67. Valencia P.M., et al. Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles. Nanomedicine 2013, 8:687-698.
68. Ma L., et al. Nanoparticles for combination drug therapy. ACS Nano 2013, 7:9518-9525.
69. Feldman E.J., et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J. Clin. Oncol. 2011, 29:979-985.
70. Batist G., et al. Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin. Cancer Res. 2009, 15:692-700.
71. Katragadda U., et al. Combined delivery of paclitaxel and tanespimycin via micellar nanocarriers: pharmacokinetics, efficacy and metabolomic analysis. PLoS ONE 2013, 8:e58619.
72. Nishimura M., et al. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov. 2013, 3:1302-1315.
73. Landen C.N., et al. EphA2 as a target for ovarian cancer therapy. Expert Opin. Ther. Targets 2005, 9:1179-1187.
74. Tabernero J., et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013, 3:406-417.
75. Xu X., et al. Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:18638-18643.
76. Xie K., et al. Error-prone translesion synthesis mediates acquired chemoresistance. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:20792-20797.
77. Doles J., et al. Suppression of Rev3, the catalytic subunit of Polζ, sensitizes drug-resistant lung tumors to chemotherapy. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:20786-20791.
78. Krishnamachari Y., et al. Nanoparticle delivery systems in cancer vaccines. Pharm. Res. 2011, 28:215-236.
79. Harris D.H., et al. Strategies for resolving patent disputes over nanoparticle drug delivery systems. Nanotechnol. Law Bus. 2004, 1:1-18.